Akron Children's Hospital > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Treating Younger Patients With T-Cell ALL or Stage II-IV T-Cell Lymphoblastic Lymphoma

Description:

For complete study information, please view the study on clinicaltrials.gov.

Interested in participating?

We are currently recruiting

Full IRB Study Title:

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

IRB Study ID:

986659-1

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

Lead Investigator

Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

Search our Site

Need Help?

Operator

Ask Children's

For Family & Patients

I am a...

Quicklinks

Find-A-Provider

Find-A-Location

Services

Health Info

About Us

Research

Search our site:

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Treating Younger Patients With T-Cell ALL or Stage II-IV T-Cell Lymphoblastic Lymphoma

Starting Locations:

Legal:

About Akron Children's